flizasertib
An orally available inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1; receptor-interacting protein 1; RIP1) with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, flizasertib inhibits RIP1-mediated signaling, which may preserve intestinal stem cells (ISCs) and prevent RIP1-mediated gastrointestinal (GI) damage in acute graft-versus-host disease (GvHD). RIP1 plays a key role in inflammation and cell death in response to tissue damage and pathogen recognition.
| Synonym: | RIP1 Inhibitor GDC-8264 RIP1 kinase inhibitor GDC-8264 RIPK1 inhibitor GDC-8264 |
|---|---|
| Code name: | GDC 8264 GDC-8264 GDC8264 RG 6287 RG-6287 RG6287 RO 7288817 RO-7288817 RO7288817 |